Scientific deep-dive

GLP-1s and Cancer: What the Cohorts Actually Show

One study found breast cancer mortality 91% lower on GLP-1s than on insulin, and no difference at all against SGLT2 inhibitors. The comparison group produced the result. What is known, and how to read this kind of evidence.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
7 min read·2 citations

Two large cohort studies looked at GLP-1 drugs and cancer. One found a modest reduction in obesity-related cancers that is probably real. The other reported that breast cancer patients on these drugs had 91% lower mortality than those on insulin or metformin. The same paper found no difference at all compared with a different diabetes drug, and that contradiction is the most instructive thing in it.

The believable finding

A nationwide cohort published in the Journal of the National Cancer Institute followed 919,609 overweight or obese adults with type 2 diabetes in the United States between 2016 and mid-2021. Across 2,086,526 person-years, 16,653 were newly diagnosed with one of thirteen obesity-related cancers.[1]

GLP-1 users had an incidence of 7.5 per 1,000 person-years against 8.1 for users of other glucose-lowering drugs, an adjusted hazard ratio of 0.87. The association held against each of six separate comparators: metformin 0.90, DPP-4 inhibitors 0.88, thiazolidinediones 0.84, sulfonylureas 0.81, SGLT2 inhibitors 0.73 and insulin 0.70.[1]

This is what a credible observational finding looks like. The effect is small. The absolute difference is smaller still: six-tenths of a case per thousand person-years. And it points the same way against every comparison group, which makes confounding less likely as the whole explanation. The strongest figure, 0.70, is against insulin, the comparison group with the sickest patients, a pattern the next section explains.

The finding that teaches you something

A 2026 cohort in JAMA Network Open examined 841,831 patients with breast cancer, and after propensity score matching compared three pairings. The results were spectacular and internally inconsistent in a specific way.[2]

One study, one drug class, three comparison groups. The right-hand column is the whole lesson.
GLP-1 compared againstMatched patientsAll-cause mortality
Non-users (patients with obesity)1,610HR 0.35 (95% CI 0.21–0.58)
Insulin or metformin (patients with T2D)2,323HR 0.09 (95% CI 0.06–0.15)
SGLT2 inhibitors (patients with T2D)4,052No significant difference

A hazard ratio of 0.09 means 91% lower mortality over ten years. No drug does that in breast cancer, chemotherapy included. A number like that comes from the comparison group, not from pharmacology.

Against insulin or metformin, the hazard ratio for death was 0.09. Against SGLT2 inhibitors, in the same study, there was no significant difference.

People on insulin have, on average, longer-standing and worse-controlled diabetes, more complications and worse general health than people started on a GLP-1. Comparing the two measures how sick each group was before anyone prescribed anything. The SGLT2 comparison removes most of that difference (similar era, similar patients, similar prescribing logic), and the effect disappears with it. The same pattern turned up in people being treated for cancer, where the insulin comparison produced the bigger and less trustworthy number.

How to read any study like this

  1. Find the comparison group before the result. “Lower risk” is meaningless until you know lower than what. A drug compared against sicker patients will always look good.
  2. Distrust enormous effects in observational data. Hazard ratios below about 0.5 in a non-randomized study are usually a description of who was prescribed the drug.
  3. Look for consistency across comparators. The JNCI result held at 0.70 to 0.90 across six; the breast cancer result went from 0.09 to nothing across three.
  4. Convert to absolute numbers. The “13% lower risk” sits on rates of 7.5 against 8.1 per 1,000 person-years, and those land very differently.
  5. Note what the authors themselves say. The breast cancer authors call for randomized trials, which is the appropriate conclusion from their own data; what the randomized trials already show for breast cancer is summarized in GLP-1 drugs and breast changes.

So what is known

GLP-1 use is associated with a slightly lower rate of obesity-related cancers in people with type 2 diabetes, by roughly a tenth, consistently across comparators. That is a real finding and a modest one, and it is entirely plausible: obesity is a recognized driver of those thirteen cancer types, and these drugs reduce obesity. A cohort of obese adults without diabetes reported a larger drop, 41%, over a median follow-up of only two years.

The randomized evidence, which we cover in the trials’ answer on cancer, points at little or no effect in either direction, which is consistent with a small association that observational data can see and short trials cannot. What is not known is whether they improve survival in people who already have cancer. The evidence claiming so does not survive contact with a fair comparison group. If you are being treated for cancer, this is a question for your oncologist, and our thyroid cancer article covers the separate matter of the boxed warning that appears on every label in this class.

None of this makes a GLP-1 a cancer treatment or a cancer preventive, and no such indication exists. Nor is it a reason for alarm in the other direction: nothing in these cohorts suggests increased cancer risk.

Frequently Asked Questions

There is a modest association. In a cohort of 919,609 overweight or obese adults with type 2 diabetes, GLP-1 users had 7.5 obesity-related cancers per 1,000 person-years against 8.1 for other glucose-lowering drugs, a hazard ratio of 0.87, consistent across six different comparison drugs. It is small, plausible and not the same as prevention.
Almost certainly not. The same study found no significant difference when GLP-1 users were compared with people taking SGLT2 inhibitors instead of insulin. The 91% figure comes from comparing against insulin users, who have more advanced diabetes and worse health before any drug is given.
Because in a non-randomized study, the two groups differ in ways beyond the drug. Insulin marks longer-standing, worse-controlled diabetes. Comparing a GLP-1 against it measures how sick each group already was. A like-for-like comparator removes most of that, and here the effect vanished when one was used.
There is no good evidence for that, and the authors of the breast cancer study call for randomized trials rather than claiming one. If you are being treated for cancer, this belongs with your oncologist.
Nothing in these cohorts suggests increased risk. The thyroid C-cell warning that appears on every label in this class is a separate question with its own evidence, covered in our thyroid cancer article.

References

  1. 1.Mao X, Zhang X, Henry L, et al. Association between glucagon-like peptidase 1 receptor agonist and obesity-related cancer in overweight or obese patients with type 2 diabetes: a nationwide cohort study Journal of the National Cancer Institute. 2025. PMID: 40632592.
  2. 2.Tatum KL, Dahman B, Stevenson A, et al. Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer JAMA Network Open. 2026. PMID: 42113513.

GLP-1s in People Being Treated for Cancer

Lower mortality and fewer hospitalizations than metformin, at a hazard ratio of 0.875. A second comparison against insulin produced a bigger number, and the bigger number is the less trustworthy one.

5 min read

GLP-1s and Cancer: The Randomized Answer

Randomized evidence finds little or no effect on obesity-related cancers: pancreatic somewhere between 9 fewer and 6 more per 10,000. The trials were not designed to look for cancer and had short follow-up.

6 min read

Cancer Risk in People Without Diabetes

A study in obese adults without diabetes found 41% lower incidence of obesity-associated cancers. The median follow-up was two years, far too short to establish that a drug prevented anything.

6 min read

The Group That Lost Least Did Best

A study compared surgery, semaglutide and a lifestyle program in young women with endometrial cancer. The group that lost the least weight had the highest tumor remission rate, and that is almost certainly not what it looks like.

6 min read

Are GLP-1s Longevity Drugs? What the Death and Outcome Data Show

GLP-1 drugs lower deaths from any cause by about 12% in people with heart disease, diabetes or kidney disease. No trial has tested them in healthy adults or measured lifespan. SELECT, FLOW, LEADER, dementia, cancer and muscle, in one place.

11 min read

Semax vs Selank: Two Russian Nasal Peptides, and Only One Is Now Covered

Semax is an ACTH fragment studied in stroke; Selank is a tuftsin analog studied in anxiety. Since October 28, 2026, HHS’s enforcement-discretion policy covers compounded intranasal Semax under 503A. Selank and Semax + Selank blends are not covered.

10 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

9.3

Embody

A flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies

7.1

Direct Meds

Compounded semaglutide at $249/month

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →